Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02076789
Other study ID # 72/2013/O/Oss
Secondary ID
Status Recruiting
Phase N/A
First received February 24, 2014
Last updated January 8, 2015
Start date March 2013
Est. completion date October 2015

Study information

Verified date January 2015
Source Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Contact Mauro Biffi
Phone 0039 051 636 3434
Email decode.registry@libero.it
Is FDA regulated No
Health authority Italy: Ministry of Health
Study type Observational

Clinical Trial Summary

This study has been designed to prospectively estimate long term complication rates (12-months and 5-years) in patients undergoing Implantable Cardioverter Defibrillator (ICD) replacement, with and without a planned transvenous lead addition for replacement or upgrade to a device capable of additional therapies; the study also evaluates the predictors of complications, the patient's management before and during the replacement procedure in clinical practice and the estimated costs related to the use of health care resources.


Description:

Based on positive outcomes from numerous randomized, controlled trials, the implantable defibrillators have been included in the current European Society of Cardiology (ESC) and American College of Cardiology / American Heart Associations (ACC/AHA) guidelines as a standard of care in selected patients, and thus ICD use is currently increasing worldwide.

In the years after initial implantation, device replacement may become necessary for battery depletion or for upgrades to more complex multi-lead ICDs. The increase in generator or lead advisories and recalls contributes further to those patients considered for replacement.

The determination of procedural adverse events is complex, and requires monitoring of both short-term complications and long-term patient outcome.

Previous retrospective series have examined complications with ICD replacements. Moreover, the more recent REPLACE registry prospectively collected 6-month complication rates in patients undergoing pacemaker or ICD generator replacement at 72 private practice and academic sites in United States. This study examined a broad range of major and minor complications and found that ICD replacements were associated with a notable complication risk, particularly when a transvenous lead addition or revision was required.

Previous retrospective series have examined complications with ICD implantation in the Italian clinical practice, showing frequent interventions for system revision and demonstrating an association between adverse events and the complexity of the implanted device (i.e. Cardiac Resynchronization Therapy CRT-D versus single- or dual-chamber ICD). Moreover, it was shown that device replacement procedures are associated with significantly higher risk of infections.

Nonetheless, detailed data on the complications of ICD replacement in the current Italian clinical practice are unavailable.

This information would be particularly important because ICD replacement-related events may be associated not only with a worse clinical outcome, but also with incremental costs to the healthcare system.

The analysis of adverse events would permit to study new preventative strategies with significant clinical as well as financial benefits. Moreover, the quantification of the complication rate after ICD replacement would permit to estimate the actual long-term cost of ICD therapy, and to assess the impact of ICD longevity on the cost-effectiveness of the therapy.

This study has been designed to prospectively estimate long term complication rates (at 12-months and 5-years) in patients undergoing ICD generator replacement. The study also evaluates predictors of complications, patient's management before and during the replacement procedure in clinical practice and the estimated costs related to the use of health care resources.

All consecutive patients with standard indications to ICD generator replacement will be enrolled In this study. The decision to perform the generator replacement or to upgrade an existing device will be made according to the investigators' clinical assessment of their patient. The study do not mandate specific surgical or implantation techniques such as venous access, use of temporary pacemakers, or surgical site choices. Any commercially available generator or lead can be included.

Patients will be followed for a 60-month period with periodical in-hospital visits or remote ICD interrogations via remote patient monitoring (RPM) systems, according to the standard hospital practice and the physician's discretion.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient implanted with a CardiacResynchronizationTherapy-Defibrillator or single chamber/dual chambers ICD device (any commercially available generator or lead can be included).

- Patient with standard indications to ICD generator replacement according to the investigators' clinical assessment.

- Patient must be able to attend all required follow-up visits at the study center.

Exclusion Criteria:

- Patient is less than 18 years of age.

- Patient is unwilling or unable to sign an authorization to use and disclose health information or an Informed Consent.

- Patient life expectancy is less than 12 months.

- Patient is participating in another clinical study that may have an impact on the study endpoints.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Ospedale "San Donato" Arezzo
Italy Ospedale Civile S.Agostino-Estense Baggiovara Modena
Italy Ospedale di Bentivoglio Bentivoglio Bologna
Italy A.O. "Papa Giovanni XXIII" Bergamo BG
Italy Azienda Ospedaliera Universitaria , Policlinico Sant'Orsola Bologna
Italy Ospedale Maggiore Bologna
Italy Università Cattolica del Sacro Cuore Campobasso
Italy Ospedale di Venere Carbonara di Bari Bari
Italy Ospedale SS. Annunziata Cento Ferrara
Italy Ospedale "Maurizio Bufalini" Cesena Forlì
Italy Ospedale Cuneo Cuneo
Italy Ospedale "San Giuseppe" Empoli
Italy A.O.S.Anna Ferrara
Italy Ospedale "Morgagni-Pierantoni" Forlì
Italy Ospedale "Padre Antero Micone" - Sestri Ponente Genova
Italy Ospedale della Misericordia Grosseto
Italy Ospedale Maggiore Lodi LO
Italy Clinica Mediterranea Napoli
Italy Ospedale Monaldi SUN Napoli
Italy A.O.U.P. "Paolo Giaccone" Palermo PA
Italy A.O. Santa Maria della Misericordia Perugia
Italy Azienda Ospedali Riuniti Marche Nord Pesaro
Italy Ospedale "Santa Maria delle Croci" Ravenna
Italy Ospedale Santa Maria Nuova Reggio Emilia
Italy Ospedale degli Infermi Rimini
Italy Policlinico Casilino Roma
Italy Policlinico Universitario "Agostino Gemelli" Rome RM
Italy A.O. San Giovanni di Dio e Ruggi di Aragona Salerno
Italy Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo FG
Italy Ospedale Santa Maria alle Scotte Siena SI
Italy Casa di Cura "Villa Verde" Taranto TA
Italy Ospedale Santa Maria di Cà Foncello Treviso

Sponsors (1)

Lead Sponsor Collaborator
Mauro Biffi

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of complications associated with the ICD replacement / upgrade that occur during a period of 12 months The primary outcome measure of this study is to estimate, at 12-months follow up, the percentage of subjects undergoing ICD generator replacement, with and without a planned transvenous lead addition for replacement or upgrade to a device capable of additional therapies, experiencing one of the pre-defined complications. 12 months No
Secondary Baseline patient's characteristics (clinical history and drug therapy) for subjects undergoing ICD replacement/upgrade This secondary outcome measure of this study is to evaluate baseline patient's characteristics or variables of procedure's management as potential predictors of complications, that will be evaluated at 30 days, at 12 months and 60 months follow up 60 months No
Secondary - Rate of complications associated with the ICD replacement / upgrade that occur during a very long-term period This extends to 60 months the results obtained with the primary objective at 12 months 60 months No
Secondary Long-term costs of ICD/upgrade procedure This secondary outcome measure of this study is to evaluate resource consumption and associated costs in terms of devices, replacement/upgrade procedures , follow-up, post-replacement/upgrade management of complications and health care resources utilization. 60 months No
See also
  Status Clinical Trial Phase
Completed NCT02323503 - Assessment of Ventricular Arrhythmia Risk After CRT-D Replacement for Patients With Primary Prevention Indication
Completed NCT00395447 - REPLACE: Implantable Cardiac Pulse Generator Replacement Registry Phase 4